Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study of CD19-BAFF CAR-T Cells Therapy for Patients With Relapsed and/or Refractory B-cell ALL and B-cell NHL

NCT06346912 is registered in ClinicalTrials.gov with Zhejiang University as lead sponsor.

NCT NCT06346912
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06346912 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study of CD19-BAFF CAR-T Cells Therapy for Patients With Relapsed and/or Refractory B-cell ALL and B-cell NHL
Lead sponsor
Zhejiang University
Phase
Phase 1
Overall status
Recruiting
Start date
May 30, 2024
Completion date
May 30, 2027
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoblastic leukemia,b-cell, non-hodgkin lymphoma,b cell